SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) have been given an average recommendation of “Moderate Buy” by the six ratings firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $10.00.

A number of equities research analysts have recently commented on SABS shares. UBS Group assumed coverage on shares of SAB Biotherapeutics in a report on Wednesday, January 7th. They issued a “buy” rating and a $7.00 target price for the company. Weiss Ratings restated a “sell (d)” rating on shares of SAB Biotherapeutics in a research report on Monday, December 29th. Guggenheim began coverage on SAB Biotherapeutics in a research note on Friday, December 19th. They set a “buy” rating and a $15.00 price objective for the company. Wall Street Zen upgraded SAB Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. Finally, Chardan Capital reissued a “buy” rating and issued a $12.00 target price on shares of SAB Biotherapeutics in a report on Thursday, December 18th.

Institutional Trading of SAB Biotherapeutics

Several hedge funds have recently made changes to their positions in SABS. ADAR1 Capital Management LLC acquired a new position in shares of SAB Biotherapeutics during the third quarter worth about $30,000. Dimensional Fund Advisors LP acquired a new stake in SAB Biotherapeutics in the third quarter valued at about $32,000. State of Wyoming purchased a new stake in SAB Biotherapeutics in the 4th quarter valued at approximately $34,000. Virtu Financial LLC acquired a new position in SAB Biotherapeutics during the 3rd quarter worth approximately $40,000. Finally, State Street Corp purchased a new position in shares of SAB Biotherapeutics during the 4th quarter worth approximately $49,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

SAB Biotherapeutics Stock Performance

Shares of SABS opened at $3.85 on Tuesday. The company’s 50 day simple moving average is $3.97 and its 200-day simple moving average is $3.14. The firm has a market cap of $183.30 million, a PE ratio of -1.25 and a beta of 0.58. SAB Biotherapeutics has a 12-month low of $1.00 and a 12-month high of $6.60. The company has a current ratio of 10.49, a quick ratio of 10.50 and a debt-to-equity ratio of 0.02.

SAB Biotherapeutics (NASDAQ:SABS) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.38. As a group, equities analysts predict that SAB Biotherapeutics will post -3.69 EPS for the current year.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.